Shares of Syneos Health Inc (NASDAQ:SYNH) have been assigned an average rating of “Buy” from the twelve ratings firms that are currently covering the company, MarketBeat reports. Three equities research analysts have rated the stock with a hold recommendation and nine have given a buy recommendation to the company. The average 12 month price target among analysts that have issued ratings on the stock in the last year is $54.75.
Several brokerages recently commented on SYNH. ValuEngine upgraded Syneos Health from a “hold” rating to a “buy” rating in a report on Monday, February 4th. Robert W. Baird set a $60.00 target price on Syneos Health and gave the company a “buy” rating in a report on Tuesday, January 8th. Zacks Investment Research downgraded Syneos Health from a “buy” rating to a “hold” rating in a report on Saturday, January 5th. Barclays dropped their target price on Syneos Health from $51.00 to $45.00 and set an “equal weight” rating on the stock in a report on Thursday, January 3rd. Finally, SunTrust Banks dropped their target price on Syneos Health to $55.00 and set a “buy” rating on the stock in a report on Wednesday, December 19th.
Get Syneos Health alerts:In related news, General Counsel Jonathan Olefson bought 750 shares of the company’s stock in a transaction that occurred on Monday, December 17th. The shares were acquired at an average cost of $41.27 per share, for a total transaction of $30,952.50. The purchase was disclosed in a document filed with the SEC, which is accessible through the SEC website. Also, CFO Jason M. Meggs bought 3,650 shares of the company’s stock in a transaction that occurred on Monday, December 17th. The shares were bought at an average price of $41.25 per share, for a total transaction of $150,562.50. The disclosure for this purchase can be found here. Company insiders own 0.57% of the company’s stock.
A number of hedge funds have recently bought and sold shares of the business. PNC Financial Services Group Inc. increased its holdings in Syneos Health by 6.4% during the 4th quarter. PNC Financial Services Group Inc. now owns 3,554 shares of the company’s stock worth $141,000 after purchasing an additional 214 shares during the last quarter. Crossmark Global Holdings Inc. increased its holdings in Syneos Health by 4.4% during the 4th quarter. Crossmark Global Holdings Inc. now owns 5,660 shares of the company’s stock worth $223,000 after purchasing an additional 240 shares during the last quarter. Virginia Retirement Systems ET AL increased its holdings in Syneos Health by 2.8% during the 4th quarter. Virginia Retirement Systems ET AL now owns 11,000 shares of the company’s stock worth $433,000 after purchasing an additional 300 shares during the last quarter. First Hawaiian Bank increased its holdings in Syneos Health by 2.9% during the 4th quarter. First Hawaiian Bank now owns 12,562 shares of the company’s stock worth $494,000 after purchasing an additional 350 shares during the last quarter. Finally, Zurcher Kantonalbank Zurich Cantonalbank increased its holdings in Syneos Health by 9.9% during the 4th quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 3,985 shares of the company’s stock worth $157,000 after purchasing an additional 360 shares during the last quarter.
Shares of NASDAQ SYNH traded up $1.25 during midday trading on Tuesday, hitting $52.66. The stock had a trading volume of 423,596 shares, compared to its average volume of 587,410. The firm has a market capitalization of $5.23 billion, a P/E ratio of 27.14, a P/E/G ratio of 1.42 and a beta of 1.51. Syneos Health has a 1-year low of $31.10 and a 1-year high of $53.95. The company has a debt-to-equity ratio of 0.99, a current ratio of 0.97 and a quick ratio of 0.97.
Syneos Health Company Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as unbundled service offerings, such as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Read More: How Short Selling Works
No comments:
Post a Comment